Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)	Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Amyloid Angiopathy, Familial, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemorrhage, Intracranial Hemorrhages, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, amyloidosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebral amyloid angiopathy, cerebral arterial disease, cerebrovascular disorder, cognitive disorder, dementia, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, intracerebral hemorrhage, intracranial arterial disease, metabolic disease, nervous system disorder, proteostasis deficiencies, psychiatric disorder, vascular disorder	Active, not recruiting	Phase 2	2026-07-21		NCT07716865

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Arctic Therapeutics	2

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Landspitali University Hospital	Reykjavik	Iceland	2